The first long-term comparison of psilocybin vs an SSRI for MDD suggests the psychedelic was associated with better overall ...

Transportation and geographic location are two of the biggest barriers to mental health care access for older adults. This ...

A study comparing psilocybin to the SSRI escitalopram found both drugs improved depressive symptoms similarly over six months ...

Pediatric patients are also more susceptible to becoming addicted to ketamine and forming substance abuse disorders.

This study aimed to explore the association between major depressive disorder (MDD) and suicide risk in dementia patients.A cohort of 625,218 individuals aged ≥40 years with dementia between 2007 and ...

The AMPLIFY trial will assess the safety and efficacy of ABX-002 when used alongside existing SSRI or SNRI treatments.

Researchers applied machine learning to predict depressive symptoms, revealing sleep quality and anxiety as key factors ...

Teva Pharma announces long term efficacy and safety of deutetrabenazine in European patients with debilitating movement disorder tardive dyskinesia: Tel Aviv, Israel Tuesday, Sept ...

STIM recently announced that additional payors have updated the coverage of TMS (transcranial magnetic stimulation). This upgrade is aimed at reducing the access barriers for patients with major ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the ...

Hoarding Disorder is classified under the category of Obsessive-Compulsive and Related Disorders in the DSM-5. It has gained ...

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine ...